Core Viewpoint - The company, once hailed as the "national snack first stock," is now facing unprecedented challenges despite its efforts to prepare for a Hong Kong IPO, which may be a desperate attempt to cover its declining performance and seek short-term financial support [1] Financial Performance - In 2024, the company achieved revenue and net profit growth, but this trend did not continue into 2025, with Q1 financial reports showing a significant net profit decline of 22.65% year-on-year and a non-recurring net profit drop of 38.31%, indicating a clear "revenue growth without profit" phenomenon [3][4] - Sales and management expenses surged, with sales expenses reaching 695 million yuan, a year-on-year increase of 17.24%, further eroding profit margins [3] - Operating cash flow decreased sharply, raising market concerns about the company's cash flow and financial stability [3] Seasonal Performance - The company has reported negative net profits in the second quarter for three consecutive years, with figures of -79.33 million yuan in 2022, -38.08 million yuan in 2023, and -18.58 million yuan in 2024, highlighting significant seasonal fluctuations in business performance [4] International Market Challenges - Since 2018, the company has attempted to expand into overseas markets, but by 2024, international revenue was only 696,800 yuan, accounting for a mere 0.01% of total revenue, raising doubts about the authenticity of its globalization strategy [5] - The company's new sub-brands, such as "Little Deer Blue" and "Raised a Hairy Child," have not performed well in the market, with "Little Deer Blue" generating 794 million yuan in revenue but showing a declining share of total revenue [5] Strategic Challenges - The company's founder has set an ambitious revenue target of 20 billion yuan by 2026, but the current market environment makes this goal seem distant [6] - The company faces intense competition in the offline market, particularly against merged competitors, making expansion efforts challenging [6] - Price wars in the snack industry are compressing profit margins, and maintaining competitiveness will require significant costs, further straining profitability [6]

（文/朱道义 编辑/张广凯） 2025年，香港资本市场迎来复苏的新格局，大量新股涌现之余，不少A股大佬也正排队卷向港股。如今，年内的 第6家"A+H"上市公司，距离诞生似乎只差临门一脚。 据港交所5月23日披露，佛山市海天调味食品股份有限公司（以下简称：海天味业、股票代码：603288.SH）通过 港交所主板上市聆讯，中金公司、高盛、摩根士丹利为联席保荐人。 回顾此次IPO进程，海天味业曾于今年1月13日向香港联交所递交发行上市申请，并于同日在港交所网站刊登了申 请资料。4月28日，中国证监会出具了《关于佛山市海天调味食品股份有限公司境外发行上市备案通知书》（国合 函[2025]748号），对海天味业发行上市备案信息予以确认。 随后在5月15日，香港联交所上市委员会举行了上市聆讯，审议通过了海天味业发行上市申请，赴港上市取得关键 性进展。 此前不久，据"独角兽早知道"独家消息，海天味业已完成香港上市管理层第二轮NDR(非交易路演)，预期交易规 模约为10亿至20亿美元(视市场反馈和条件而定)。 在刚刚过去的2025年一季度，海天味业实现营收83.15亿元，同比增长8.08%；实现扣非净利润21.47 亿元，同 ...

Core Viewpoint - Hong Kong Stock Exchange (HKEX) has seen a significant increase in IPO activities in 2023, with total fundraising exceeding 76 billion HKD, a more than sevenfold increase compared to the same period last year, positioning it as the top global fundraising venue for IPOs in 2025 [2][3]. Group 1: IPO Market Performance - As of May 21, 2023, HKEX has welcomed 23 new listings, including notable companies like Mixue Ice City and CATL, which have set new records for IPO subscriptions and fundraising [2]. - The fundraising amount in Hong Kong has approached 90% of the total for the previous year, reflecting a strong recovery in the IPO market [2]. - HKEX has received nearly 100 IPO applications and is processing around 150 applications, indicating a robust pipeline of potential listings [3]. Group 2: Policy Changes and Market Reforms - The launch of the "Tech Company Fast Track" aims to streamline the listing process for technology and biotech companies, allowing confidential submissions and creating a "green channel" for these firms [4][5]. - HKEX has been progressively adjusting its policies to attract more high-growth tech companies, including the introduction of new listing frameworks and lowering entry barriers for specialized tech firms [4][5]. - Recent reforms to the IPO pricing mechanism are considered the most comprehensive in three decades, aimed at enhancing market competitiveness and improving the efficiency of new stock pricing [5]. Group 3: Trends in Listings - There is a notable trend of companies opting for "A+H" listings, with over 40 companies already applying or announcing plans to list in Hong Kong after being listed in mainland China [6]. - The return of Chinese concept stocks to Hong Kong is anticipated, with many companies considering dual listings or secondary listings in response to favorable market conditions [6][7]. - International companies, including those from Singapore and Thailand, are also increasingly choosing HKEX for their listings, further diversifying the market [7]. Group 4: Financial Performance and Future Outlook - HKEX has reported record financial results, with total revenue and other income reaching 22.4 billion HKD in 2024, a 9% increase from 2023 [8]. - The first quarter of 2025 saw HKEX achieving historical highs in both revenue and profit, with revenue of nearly 6.9 billion HKD, a 32% year-on-year increase [8]. - Strategic initiatives are underway to enhance liquidity and market vitality, including partnerships to expand the range of fixed income and currency products [9].

Core Viewpoint - Heng Rui Pharmaceutical successfully listed on the Hong Kong Stock Exchange on May 23, 2023, achieving a market capitalization exceeding HKD 390 billion, marking the largest pharmaceutical IPO of the year [4][5]. Company Overview - Heng Rui Pharmaceutical's IPO price was set at HKD 44.05, with the stock opening nearly 30% higher [4]. - The cornerstone investors for this IPO included notable entities such as the Government of Singapore Investment Corporation (GIC), Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital, with total subscriptions exceeding HKD 4.1 billion [4]. - The company was founded by Sun Piaoyang, who transformed a small pharmaceutical factory into a major player in the Chinese pharmaceutical industry [6][7]. Financial Performance - For the first three quarters of 2024, Heng Rui reported revenues of CNY 20.19 billion and a net profit of CNY 4.62 billion, with net profit reaching a historical high [11]. - The sales revenue from innovative drugs accounted for 47.7% of total revenue, indicating a significant contribution from generic drugs [11]. - The proportion of innovative drug sales increased from 38.1% in 2022 to 43.4% in 2023 [11]. Strategic Direction - The company aims to enhance its global presence through the Hong Kong listing, which is seen as a bridge for international expansion and brand recognition [12]. - The funds raised from the IPO will be used to build new production and R&D facilities both domestically and internationally [12]. Market Context - The Hong Kong stock market has seen a surge in IPO activity in 2023, with significant listings such as Ningde Times and Mixue Ice City, contributing to a total fundraising amount exceeding HKD 60 billion, a sixfold increase compared to the previous year [18]. - The current market environment is favorable for new listings, with a substantial pipeline of around 150 applications under review at the Hong Kong Stock Exchange [18][19].

以下文章来源于天天IPO ，作者周佳丽 天天IPO . 投资界（PEdaily.cn）旗下，专注IPO动态 欢迎加入投资界读者群 港股沸腾。 作者 I 周佳丽 报道 I 投资界-天天IPO 投资界-天天IPO获悉，今天（5月23日），恒瑞医药正式登陆港交所，实现"A+H"两地上 市。此次IPO，恒瑞医药发行价44.05港元，开盘大涨近30%，市值超3 900亿港元，缔造 今年最大医药IPO。 这一次赴港上市，恒瑞医药基石阵容引人注目，包括新加坡政府投资公司（GIC）、景 顺、瑞银全球资产管理集团、高瓴、博裕资本等，认购总规模逾4 1亿港元。 说起恒瑞医药，离不开灵魂人物——孙飘扬。来自江苏淮安，孙飘扬一度被视为中国"药 神 " ， 白 手 起 家 将 不 知 名 的 小 药 厂 做 到 中 国 医 药 界 巨 头 ， 20 00 年 登 陆 上 交 所 成 为 A 股 药 王。直到今天，6 6岁的孙飘扬再一次IPO敲钟。 透 过 恒 瑞 医 药 ， 我 们 看 到 港 交 所 已 经 集 聚 宁 德 时 代 、 蜜 雪 冰 城 、 泡 泡 玛 特 等 一 批 超 级 IPO 。 港 交 所 CEO 陈 翊 庭 ...

透过恒瑞医药，我们看到港交所已经集聚宁德时代、蜜雪冰城、泡泡玛特等一批超级IPO。港交所CEO 陈翊庭透露，目前正在审理的上市申请约有150宗，当中不乏龙头企业，这是前所未有的一幕。 投资界-天天IPO获悉，今天（5月23日），恒瑞医药正式登陆港交所，实现"A+H"两地上市。此次IPO， 恒瑞医药发行价44.05港元，开盘大涨近30%，市值超3900亿港元，缔造今年最大医药IPO。 这一次赴港上市，恒瑞医药基石阵容引人注目，包括新加坡政府投资公司（GIC）、景顺、瑞银全球资 产管理集团、高瓴、博裕资本等，认购总规模逾41亿港元。 说起恒瑞医药，离不开灵魂人物——孙飘扬。来自江苏淮安，孙飘扬一度被视为中国"药神"，白手起家 将不知名的小药厂做到中国医药界巨头，2000年登陆上交所成为A股药王。直到今天，66岁的孙飘扬再 一次IPO敲钟。 孙飘扬现身，恒瑞医药IPO，市值3900亿 故事从孙飘扬说起。 1958年生于江苏淮安金湖，孙飘扬1982年从中国药科大学化学制药专业毕业，后便被分配到连云港制药 厂，也就是恒瑞医药的前身，担任技术员。后来由于勤奋踏实，他被连云港制药厂的上级——医药工业 公司调任过去，担任副科 ...

Core Viewpoint - The recent IPOs in the Hong Kong stock market have shown strong profitability, with significant price increases for newly listed stocks like 恒瑞医药 (Hengrui Medicine) and MIRXES-B during the dark pool trading period [1][2]. Company Summaries 恒瑞医药 (Hengrui Medicine) - 恒瑞医药, an established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D expenditure of 29.4% of total revenue in 2024 [6]. - The company has returned approximately RMB 80.29 billion in cash dividends to shareholders since its A-share listing, which is 16.8 times the capital raised at that time [6]. - 恒瑞医药 has 19 marketed innovative drugs and over 90 new molecular entities in clinical or later stages of development [6]. - The total revenue for 恒瑞医药 is projected to be RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of about 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of approximately 4% [6]. - The revenue contribution from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024, while the contribution from generic drugs decreased from 60.3% in 2022 to 42.0% in 2024 [7]. MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in microRNA technology for disease screening and diagnostics, particularly in cancer detection [7]. - The company is one of the few globally to have received regulatory approval for molecular cancer screening IVD products, and is the first to receive such approval for molecular gastric cancer screening [7]. - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [7]. - The subscription multiple for MIRXES-B is significantly lower than that of 恒瑞医药, with 25 times compared to 恒瑞医药's 409 times [7]. Market Trends - The recent trend in the Hong Kong IPO market shows a strong upward movement, with only 6 out of 23 newly listed companies this year experiencing a decline on their first trading day, while others have seen substantial gains [8].

Core Viewpoint - The article highlights the significant price increases of two new stocks, 恒瑞医药 (Hengrui Medicine) and MIRXES-B, during the dark trading period before their listing on the Hong Kong stock market, indicating strong market interest and potential investment opportunities. Group 1: Hengrui Medicine - Hengrui Medicine, a well-established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D investment of 29.4% of total revenue in 2024 [3] - The company has a diverse portfolio with 19 marketed innovative drugs and over 90 in clinical or later stages of development [4] - Hengrui's total revenue is expected to reach RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of approximately 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of about 4% [4] - The sales revenue from innovative drugs has increased from 38.1% of total revenue in 2022 to 43.4% in 2023, and is projected to reach 46.3% in 2024, while sales from generic drugs are decreasing [4] Group 2: MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in miRNA technology for disease screening and diagnostics, particularly in cancer detection [4] - The company is one of the few globally to have received regulatory approval for its molecular cancer screening IVD products, including the first approval for molecular gastric cancer screening [4] - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [5] - The subscription ratio for MIRXES-B is significantly lower than that of Hengrui Medicine, with 25 times compared to Hengrui's 409 times [6]

Core Viewpoint - The article discusses the upcoming IPO of FWD Group, led by Richard Li, the son of Li Ka-shing, highlighting its growth and expansion in the insurance sector across Asia-Pacific, particularly its significant customer base from mainland China [3][4][6]. Group 1: Company Overview - FWD Group has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Richard Li as its leader, who has established the company through strategic acquisitions since 2013 [3][5]. - The company has approximately 60,000 policyholders from mainland China, indicating a strong market presence [4][6]. - FWD Group's business model focuses on customer-centric and digital empowerment strategies, leading to rapid growth in the insurance market [5][6]. Group 2: Financial Performance - From 2014 to 2024, FWD Group's annualized new premiums are projected to grow 5.2 times, from $309 million to $1.916 billion [6]. - The company reported net insurance and investment performance of $493 million, $470 million, and $911 million for the years 2022 to 2024, respectively, with a turnaround to profitability expected in 2024 [7]. - The annualized new premium from mainland Chinese visitors has seen a growth of 6.3 times from 2022 to 2024, showcasing the potential for further expansion in this market [7]. Group 3: Market Context - The Hong Kong IPO market is experiencing a resurgence, with significant listings such as CATL and Heng Rui Pharmaceutical, indicating a robust environment for new public offerings [13][14]. - The total fundraising amount from new IPOs in Hong Kong has exceeded HKD 60 billion, marking a more than sixfold increase compared to the previous year [13][15]. - The sentiment among investors has shifted positively, with a growing interest in Hong Kong listings, contrasting with previous perceptions of low liquidity and valuation issues [15].

在深度共话环节，中信建投投资银行委员会执行总经理赵旭、松禾资本合伙人赵亮、启赋资本合伙人唐华林、华商律师事务所合伙人徐舜芝、毕马威中国审 计合伙人徐司辞围绕"港股IPO最新动向带给企业及投资机构的机遇及挑战"开展热烈讨论。从上市中介机构视角出发，嘉宾们就审计实操、募集资金管理、 港股再融资等内容分享见解，并深入探讨港股上市备案规范性要求、港股与A股财务会计处理差异等企业关注的焦点问题。 记者了解到，近年来，赴港上市热度持续攀升。2024年4月，中国证监会发布《五项资本市场对港合作措施》，明确支持内地行业龙头企业赴港上市；同年 10月，香港证监会和港交所联合声明，针对符合资格的A股公司推出快速审批时间表。5月7日，中国证监会主席吴清表示，将创造条件支持优质中概股企业 回归内地和香港股市。如今，香港已成为A股公司境外融资上市及中概股回流上市的首选平台。未来，深证企服中心将持续发挥平台纽带作用，整合深港两 地资源，为更多优质企业提供上市辅导、融资对接等全周期服务，搭建深港金融合作桥梁，助力企业借助资本市场实现跨越式发展。 （本文图片由前海管理局提供） 深圳商报·读创客户端记者 范宏韬 5月16日，在深圳市委金融办、 ...